{'fraction_non_alphanumeric': 0.022026431718061675, 'fraction_numerical': 0.02378854625550661, 'mean_word_length': 5.241758241758242, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
FLUCONAZOLE USAGE AT THE OCHSNER FOUNDATION HOSPITAL: 1-YEAR REVIEW

The objective of this study was to evaluate the use and efficacy of fluconazole in a clinical setting under nonprotocol conditions. All patients receiving fluconazole from May 1, 1990, through April 30, 1991, were identified, and the charts were reviewed in a retrospective fashion to get a more accurate representation of how and why fluconazole was being used in our institution. There were 215 patients who received 272 courses of fluconazole therapy during the study year. The most common reasons for initiating fluconazole therapy were the presence of yeast in the urine, continuation of home medications, fungemia, and fungal pneumonia. Candida albicans was the most frequently isolated fungus. Of the 272 courses of therapy, 58% were cured or improved, 11% were mycologic failures, and 31% had an indeterminate outcome. Thirty-eight percent of the courses of therapy included potentially unnecessary concomitant topical and systemic antifungal therapy. Fluconazole is widely used in our institution with a high degree of success and positive clinical outcome.